# Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

> **NCT02209805** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 49 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIRB 796 BS, low dose
- **DRUG:** BIRB 796 BS, high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02209805
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2001-03
- **Final completion:** —
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209805, "Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02209805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*